Trial Profile
Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms PAVE
- 01 Jun 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 18 Apr 2022 Planned End Date changed from 1 Sep 2021 to 1 Apr 2023.
- 05 Apr 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Sep 2021.